Point-of-care systems for rapid DNA quantification in oncology

Tumori

Volumn 94, Issue 2, 2008, Pages 216-225

  Bianchessi, Marco ^a   Burgarella, Sarah ^a   Cereda, Marco ^b  

^a STMICROELECTRONICS   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Lab on chip; Molecular diagnostics; Oncology; Point of care

Indexed keywords

GAMMA INTERFERON;

CANCER RESEARCH; CONFERENCE PAPER; ELECTRONICS; ELECTROPHORESIS; HUMAN; MEDICAL PRACTICE; MEDICINE; MICROARRAY ANALYSIS; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLOGY; POINT OF CARE TESTING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TECHNOLOGY; TRAINING; TUMOR IMMUNITY; WILD TYPE;

EID: 45249102901     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400214     Document Type: Conference Paper

References (96)

1. Ross IM: The invention of the transistor. Proceedings of the IEEE, 86(1): 7-28, 1998.
2. Moore GE: Cramming more components onto integrated circuits. Electronics, 38(8), 1965.
3. Zhang GQ: "More than Moore" - The changing international landscape, strategy and solutions of micro/nanoelectronics. Electronic Packaging Technology, ICEPT 2007, 8th International Conference, Aug. 2007, Shanghai, China, 2007.
4. Meinhart CD, Zhang H: The flow structure inside a microfabricated inkjet printhead. Journal of Microelectromechanical Systems, 9(1): 67-75, 2000.
5. Yazdi N, Ayazi F, Najafi K: Micromachined inertial sensors. Proceedings of the IEEE, 86(8): 1640-1659, 1998.
6. Skoog DA, Holler FJ, Crouch SR: Principles of Instrumental Analysis 6th ed., Thomson Brooks/Cole Publishing, Belmont, CA 2007.
7. Shalon D, Smith SJ, Brown PO: A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res, 6: 639-645, 1996.
8. Maurer K, Cooper J, Caraballo M, Crye J, Suciu D, Ghindilis A, Leonetti JA, Wang W, Rossi FM, Stover AG, Larson C, Gao H, Dill K, McShea A: Electrochemically generated Acid and its containment to 100 micron reaction areas for the production of DNA microarrays. PLoS ONE, Dec 20;1:e34, 2006.
9. Dill K, Ghindilis, Schwarzkopf K: Multiplexed analyte and oligonucleotide detection on microarrays using several redox enzymes in conjunction with electrochemical detection. Lab Chip, 6: 1052-1055, 2006.
10. Andrey L: CombiMatrix oligonucleotide arrays: Genotyping and gene expression assays employing electrochemical detection. Biosensors and Bioelectronics, DOI: 10.1016/j.bios.2006.06.024, 2006.
11. Liu RH, Nugyen T, Schwarzkopf K, Fuji HS, Petrova A, Siuda T, Peyvan K, Bizak M, Danley D, McShea A: A Fully Integrated Miniature Device for Automated Gene Expression DNA Microarray Processing. Analytical Chemistry, 78: 1980-1986, 2006.
12. Liu RH, Dill K, Fuji HS, McShea A: Integrated microfluidic biochips for DNA microarray analysis. Expert Review of Molecular Diagnostics, 6(2): 253-261, 2006.
13. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB: Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol Biol Cell, 9: 3273-3297, 1998.
14. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD: Functional discovery via a compendium of expression profiles. Cell, 102: 109-126, 2000.
15. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA, 95: 14863-14868, 1998.
16. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403: 503-511, 2000.
17. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med, 194: 1639-1647, 2001.
18. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A, 98: 13784-13789, 2001.
19. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R: Gene-expression profiles in hereditary breast cancer. N Engl J Med, 344: 539-548, 2001.
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA: Molecular portraits of human breast tumours. Nature, 406: 747-752, 2000.
21. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M: Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530-536, 2002.
22. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98: 10869-10874, 2001.
23. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet, 23: 41-46, 1999.
24. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ: STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol, 20: 325-334, 2002.
25. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)- overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 61: 8887-8895, 2001.
26. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr.: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol, 29: 37-46, 2002.
27. Herbst RS, Langer CJ: Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol, 29: 27-36, 2002.
28. Arjomand A, Kumar A: Integration of RNAi into drug discovery. Current Drug Discovery, 2003.
29. Oleinikov AV, Zhao J, Gray MD: RNA interference by mixtures of siRNAs prepared using custom oligonucleotide arrays. Nucleic Acids Res, 7; 33(10):e92, 2005.
30. Kumar A, Anderson B, Dill K, Detection Technologies, IVD Technology, 2005.
31. Kumar A, Anderson B, Dill K, Electrochemical detection for microarray IVD applications, IVD Technology, 2005.
32. Consolandi C, Severgnini M, Frosini A, Caramenti G, De Fazio M, Ferrara F, Zocco A, Fischetti A, Palmieri M, De Bellis G: Polymerase chain reaction of 2-kb cyanobacterial gene and human anti-alpha1-chymotrypsin gene from genomic DNA on the In-Check single-use microfabricated silicon chip. Anal Biochem, 353(2):191-197, 2006.
33. Bernard PS, Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem, 48(8): 1178-1185, 2002.
34. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst, 93(19): 1458-64, 2001.
35. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K, Thiesen HJ: FasL: Fas ratio - a prognostic factor in breast carcinomas. Cancer Res, 60: 822-828, 2000.
36. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP: Elevated levels of connective tissue growth factor, WISP-I, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res, 61: 8917-8923, 2001.
37. Ginzinger DG, Godfrey TE, Nigro J, Moore DH, Suzuki S, Pallavicini MG, Gray JW, Jensen RH: Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res, 60: 5405-5409, 2000.
38. Kariyazono H, Ohno T, Ihara K, Igarashi H, Joh K, Ishikawa S, Hara T: Rapid detection of the 22q11.2 deletion with quantitative real-time PCR. Mol Cell Probes, 15: 71-73, 2001.
39. Nigro JM, Takashimi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K: Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol, 158: 1253-1262, 2001.
40. Oliver DH, Thompson RE, Griffin CA, Eshleman JR: Use of single nucleotide polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis. J Mol Diagn, 2: 202-208, 2000.
41. Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, Kaneto T, Mori M, Kirito K, Toshima M, Nakamura Y, Saito K, Kano Y, Furusawa S, Ozawa K, Mano H: Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood, 98: 422-427, 2001.
42. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM: Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res, 61: 6885-6891, 2001.
43. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlin M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res, 62: 3581-3586, 2002.
44. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ: Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst, 94: 1614-1619, 2002.
45. Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J: Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol, 39: 4269-4273, 2001.
46. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol, 163: 6867-6875, 1999.
47. Mocellin S, Ohnmacht GA, Wang E, Marincola FM: Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer, 93: 236-242, 2001.
48. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM: Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol, 167: 1809-1820, 2001.
49. Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H: Detection of gene amplification in intraductal and infiltrating breast cancer by laser-assisted microdissection and quantitative real-time PCR. Pathobiology, 68: 173-179, 2000.
50. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol, 158: 419-429, 2001.
51. Panelli MC, Wang E, Monsurro V, Marincola FM: The role of quantitative PCR for the immune monitoring of cancer patients. Expert Opin Biol Ther, 2: 537-544, 2002.
52. Housseau F, Lindsey KR, Oberholtzer SD, Gonzales MI, Boutin P, Moorthy AK, Shankara S, Roberts BL, Topalian SL: Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. J Immunol Methods, 266: 87-103, 2002.
53. Wang E, Marincola FM: A natural history of melanoma: serial gene expression analysis. Immunol Today, 21: 619-623, 2000.
54. Krauter J, Heil G, Ganser A: The AML1/MTG8 fusion transcript in t(8;21) positive AML and its implication for the detection of minimal residual disease; malignancy. Hematology, 5: 369-381, 2001.
55. Marcucci G, Livak KJ, BI W, Strout MP, Bloomfield CD, Caligiuri MA: Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia, 12: 1482-1489, 1998.
56. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H: Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia, 6: 495-499, 1992.
57. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW: The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol, 79: 424-431, 2000.
58. Hochhaus A, Reiter A, Skladny H, Reichert A, Saussele S, Hehlmann R: Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res, 144, 36-45, 1998.
59. Hardling M, Wei Y, Palmqvist L: Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. Med Oncol, 21: 349-358, 2004.
60. Gabert J: Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease. Haematologica, 84(Suppl. EHA-4): 107-109, 1999.
61. Emig M, Saussele S, Wittor H: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia, 13: 1825-1832, 1999.
62. Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B: Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia, 13: 1383-1389, 1999.
63. Olavarria E, Kanfer E, Szydlo R: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukaemia. Blood, 97: 1560-1565, 2001.
64. Preudhomme C, Revillion F, Merlat A: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia, 13: 957-964, 1999.
65. Barthe C, Mahon FX, Gharbi MJ, Faberes C, Bilhou-Nabera C, Hochhaus A, Reiffers J, Marit G: Expression of interferon-α (IFN-α) receptor 2c at diagnosis is associated with cytogenetic response in IFN-α-treated chronic myeloid leukaemia. Blood, 97: 3568-2573, 2001.
66. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg, 127: 392-399, 1992.
67. D'Cunha J, Corfits AL, Herndon JE, Kern JA, Kohman LJ, Patterson GA, Kratzke RA, Maddaus MA. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer - preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg, 123: 484-491, discussion 491, 2002.
68. Mitas M, Mikhitarian K, Walters C, Baron PL, Elliot BM, Brothers TE, Robinson IG, Metcalf JS, Palesch YY, Zhang Z1 Gillanders WE1 Cole DJ: Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer, 93: 162-171, 2001.
69. Raja S, El-Hefnawy T, Kelly LA, Chestney ML, Luketich JD, Godfrey TE: Temperature-controlled primer limit for multiplexing of rapid, quantitative reverse transcription-PCR assays: application to intraoperative cancer diagnostics. Clin Chem, 48: 1329-1337, 2002.
70. Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, Tabiti K: Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res, 7: 3423-3429, 2001.
71. Van Trappen PO, Gyselman VG, Lowe DG, Ryan A, Oram DH, Bosze P, Weekes AR, Shepherd JH, Dorudi S, Bustin SA, Jacobs IJ: Molecular quantification and mapping of lymphnode micrometastases in cervical cancer. Lancet, 357: 15-20, 2001.
72. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol, 18: 3651-3364, 2000.
73. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol, 19: 2714-2721, 2001.
74. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ: Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer, 77: 2267-2273, 1998.
75. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S: Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol, 156: 839-847, 2000.
76. Ziegler A: Circulating DNA: a new diagnostic gold mine? Cancer Treat Res, 28: 255-271, 2002.
77. Linder S: Determining tumour apoptosis and necrosis in patient serum using cytokeatin 18 as a biomarker. Cancer Lett, 214: 1-9, 2004.
78. Johnson PJ: Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem, 48: 1186-1193, 2002.
79. Shao ZM, Wu J, Shen ZZ, Nguyen M: p53 mutation in plasma and its prognostic value in breast cancer patients. Clin Cancer Res, 7: 2222-2227, 2001.
80. Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ: Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol, 11: 1097-104, 2000.
81. WU TL: Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta, 321: 77-87, 2002.
82. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res, 60: 2155-2162, 2000.
83. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res, 61: 2505-2512, 2001.
84. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med, 1: 1029-1034, 1995.
85. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer, 14: 71-75, 1995.
86. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med, 2: 811-814, 1996.
87. Huang Y: Electric manipulation of bioparticles and macromolecules on microfabricated electrodes. Anal Chem, 73: 1549-1559, 2001.
88. Hu X: Marker-specific sorting of rare cells using dielectrophoresis. Proc Natl Acad Sci USA, 102(44): 15757-15761, 2005.
89. Fu LM: Manipulation of microparticles using new modes of traveling-wave-dielectrophoretic forces: numerical simulation and experiments. IEEE/ASME Transaction on Mechatronics, 9(2): 377-383, 2004.
90. Yang J: Dielectric properties of human leukocyte subpopulations determined by electrorotation as a cell separation criterion. Biophysical Journal, 76: 3307-3314, 1999.
91. Yang J: Differential analysis of human leukocytes by dielectrophoretic field-flow-fractionation. Biophysical Journal, 78: 2680-2689, 2000.
92. Minerik A, Zhou R, Takhistov P, Chang HC: Manipulation and characterization of red blood cells with alternating current fields in microdevices. Electrophoresis, 24: 3703-3717, 2003.
93. Borgatti M: Separation of white blood cells from erythrocytes on a dielectrophoresis (DEP) based Lab-on-a-chip device. Int Jour of Molecular Medicine, 15: 913-920, 2005.
94. Altomare L, Borgatti M: Levitation and Movement of Human Tumor Cells using a printed circuit board device based on software controlled dielectrophoresis. Biotechnol Bioengin, 82(4), 474-479, 2003.
95. Becker F, Wang XB, Huang Y, Pethig R, Vykoukal J, Gascoyne P: Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Nat Acad Sci, 92: 860-864, 1995.
96. Das CM, Becker F, Vernon S, Gascoyne P: Dielectrophoretic segregation of different human cell types on microscopic slides. Anal Chem, 77(9): 2708-2719, 2005.